Like pulmonary tissue, ACE2 immunoreactivity in the left ventricle (LV) was enhanced in compensated and decompensated CHF subgroups as compared to sham controls (1.72 ± 0.23; P < .05, 1.32 ± 0.14; P = NS vs 1.0 ± 0.01, respectively) (Figure 2D). The gene discussed is ACE2; the disease is congestive heart failure.